Transparency Market Research
In view of the evolving lifestyle and increasing stress levels in life that affect the fertility-related illness, the growing incidence of male hypogondism in the geriatric population is anticipated to be significant drivers in the human market for acute gonadotropin (HCG) in the forecasted era. The transformation to gonadotropin therapy is anticipated to provide profitable possibilities for the development of the worldwidehCG market for several threatening conditions such as infertility, cryptorchidism and others.
Human chorionic gonadotropin (hCG) is part of the gonadotropin hormone family and produces placenta naturally. The HCG hormone helps a woman's ovarian to develop ordinary egg and stimulates ovulation egg release. It may be obtained by recombinant DNA technology from the urinary tract of pregnant females or from crops of genetically modified cells. Some HCG products come with a powdered liquid, which must then be combined and drawn in a syringe. Single-dose prefilled syringes are available in other products. It is commonly used to treat issues associated with infertility in females and to boost the number of sperm in males. It is also used in the treatment of cryptorchidism in young children when the testicles normally don't fall into the scrotum.
Key players working within the hCG sector have powerful demand for natural sources of gonadotropins, which in latest years has been marked by a major market trend, contributing significantly to this segment's revenues.
Rise in availability of treatment and services regarding infertility and increase in awareness about therapeutics for infertility issues are boosting the demand for human chorionic gonadotropin (hcG) hormone in developing countries. Increasing prevalence of hypogonadism-related disorders in males, especially in elderly men, is a primary driver of the human chorionic gonadotropin (hCG) market as recently hcG hormone is also used in treating males hypogonadism. Efforts of global health organizations and voluntary organizations for improving the sexual health of people in underdeveloped countries are also stoking the demand for hCG hormone. In addition, sedentary lifestyle and stress concerning personal and professional life have also led to fertility-related issues. Urban women tend to seek medical help for women-centric ailments that may impact the quality of life. Rise in elderly women population is another factor propelling the growth of human chorionic gonadotropin (hCG) market. However, FDA has issued certain warnings against the side-effects associated with using human chorionic gonadotropin as a treatment, which is anticipated to act as a restraint to the growth of the human chorionic gonadotropin (hcG) market in the near future.
The global human chorionic gonadotropin (hCG) market can be segmented on the basis of technology, therapeutic area, end-user, and region. Based on technology, the market can be divided into natural source extraction and recombinant technology. In terms of therapeutic area, the market can be classified into male hypogonadism, infertility treatment in women, oligospermic treatment, and others. Among these, infertility treatment in women constitutes the dominant share of the global human chorionic gonadotropin market. On the basis of end-user, the market can be segmented into fertility clinics, research institutions, and others.
Geographically, the global human chorionic gonadotropin (hCG) market can be distributed into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are expected to remain the leading market for human chorionic gonadotropin due to focus on innovation in technology to introduce new, advanced techniques with more particular treatment; better spotlight on infertility treatment, and presence of significant global pharmaceutical and biotechnology associations in the regions. The human chorionic gonadotropin (hCH) market in Asia Pacific is projected to grow rapidly during the forecast period. Increase in patient population and rise in awareness regarding health care treatment facilities and services are fuelling the growth of the human chorionic gonadotropin (hCG) market.
Major players operating in the global women health diagnostics market include Bristol Myers Squibb Company, Merck & Co., Inc., Cigna, Lee BioSolutions Inc., Scripps Laboratories, Ferring Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Sanzyme, and LUPIN.
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
The main aim of the report is to:
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.